EOC
MCID: OVR094
MIFTS: 43

Ovarian Epithelial Cancer (EOC) malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Ovarian Epithelial Cancer

Aliases & Descriptions for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 50
Ovarian Epithelial Carcinoma 50 29
Epithelial Ovarian Cancer 50 69
Ovarian Cancer, Epithelial 50
Eoc 50

Classifications:



Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as ovarian epithelial carcinoma, is related to ovarian cancer, somatic and ovarian cancer. An important gene associated with Ovarian Epithelial Cancer is MUC4 (Mucin 4, Cell Surface Associated), and among its related pathways/superpathways are Innate Immune System and Immune response IL-23 signaling pathway. The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include t cells, endothelial and ovary, and related phenotypes are endocrine/exocrine gland and integument

Related Diseases for Ovarian Epithelial Cancer

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

MGI Mouse Phenotypes related to Ovarian Epithelial Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.73 AKT2 BIRC5 PHB PIK3CA PTGS1 PTGS2
2 integument MP:0010771 9.55 AKT2 PHB PIK3CA PTGS1 PTGS2
3 neoplasm MP:0002006 9.26 AKT2 PIK3CA PTGS1 PTGS2
4 reproductive system MP:0005389 9.02 PTGS2 AKT2 PHB PIK3CA PTGS1

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 484)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
5
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1 763113-22-0 23725625
6
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
7 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
8 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
10 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
18
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
19
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 119413-54-6, 123948-87-8 60700
20
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
21
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
22
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
23
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
24
Ifosfamide Approved Phase 2, Phase 3, Phase 1 3778-73-2 3690
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Mechlorethamine Approved Phase 2, Phase 3, Phase 1 51-75-2 4033
27
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
28
Oxaliplatin Approved, Investigational Phase 3,Phase 1,Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
29
Lenograstim Approved Phase 3,Phase 1,Phase 2 135968-09-1
30
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
31
Pancrelipase Approved Phase 3,Phase 2,Phase 1 53608-75-6
32
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
34
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
35
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757 53477783
36
Morphine Approved, Investigational Phase 3 57-27-2 5288826
37
Captopril Approved Phase 3 62571-86-2 44093
38
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
39
Ribavirin Approved Phase 3 36791-04-5 37542
40
Fluconazole Approved Phase 3 86386-73-4 3365
41
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
42
Trastuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 180288-69-1 9903
43
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
44
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
45
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
46
Itraconazole Approved, Investigational Phase 3,Phase 1,Phase 2 84625-61-6 55283
47
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
48 Sodium thiosulfate Approved Phase 3
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Alvimopan Approved Phase 3 156053-89-3 5488548

Interventional clinical trials:

(show top 50) (show all 1220)
id Name Status NCT ID Phase
1 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4
2 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4
3 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4
4 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4
5 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3
6 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
7 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
8 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3
9 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3
10 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
11 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3
12 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
13 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Unknown status NCT02328716 Phase 3
14 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3
15 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3
16 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3
17 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3
18 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3
19 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
20 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3
21 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
22 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
23 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Completed NCT00004166 Phase 3
24 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
25 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3
26 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3
27 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3
28 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) Completed NCT01684878 Phase 3
29 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3
30 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3
31 Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer Completed NCT00002894 Phase 3
32 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3
33 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3
34 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3
35 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer Completed NCT00102414 Phase 3
36 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3
37 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
38 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
39 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3
40 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3
41 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3
42 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer Completed NCT00043082 Phase 3
43 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3
44 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3
45 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3
46 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3
47 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3
48 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3
49 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
50 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

id Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 29

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

39
T Cells, Endothelial, Ovary, Appendix

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 80)
id Title Authors Year
1
Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. ( 27017986 )
2016
2
Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. ( 27445438 )
2016
3
Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. ( 25609006 )
2015
4
Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway. ( 26261554 )
2015
5
Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. ( 26554540 )
2015
6
Overexpression of Class III I^-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. ( 26198101 )
2015
7
Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. ( 26137074 )
2015
8
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. ( 26408685 )
2015
9
Prognostic Factors for Ovarian Epithelial Cancer in the Elderly: A Case-Control Study. ( 25768081 )
2015
10
Inhibitory role of prohibitin in human ovarian epithelial cancer. ( 24966933 )
2014
11
Ovarian sarcoma carries a poorer prognosis than ovarian epithelial cancer throughout all FIGO stages: a single-center case-control matched study. ( 25503164 )
2014
12
The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells. ( 23254909 )
2013
13
Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. ( 24133590 )
2013
14
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. ( 23652306 )
2013
15
Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. ( 23708102 )
2013
16
Over-expression of semaphorin4D, hypoxia-inducible factor-1I+ and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. ( 23202951 )
2012
17
Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via I^1 integrin and PTEN signals. ( 23013730 )
2012
18
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 22895947 )
2012
19
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. ( 23189165 )
2012
20
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. ( 22985132 )
2012
21
Ovarian epithelial cancer stem cells. ( 21666993 )
2011
22
Novel approaches to quantify estradiol-induced loss of ERI^1 protein in older mouse ovarian surface epithelium: new tools to assess the role of ER protein subtypes in predisposing to ovarian epithelial cancer? ( 21773845 )
2011
23
[Effects of PTEN over-expression on phosphatidyl inositol 3-kinase/protein kinase B signal pathway in ovarian epithelial cancer cells]. ( 21092549 )
2010
24
A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer. ( 20600897 )
2010
25
High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. ( 20811671 )
2010
26
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer. ( 19945796 )
2010
27
Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. ( 21074685 )
2010
28
Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. ( 19181441 )
2009
29
Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. ( 18676764 )
2008
30
Multitargeting ovarian epithelial cancer: adding the old to the new. ( 18349413 )
2008
31
[Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. ( 19173805 )
2008
32
[Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens]. ( 18476518 )
2007
33
Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. ( 17712227 )
2007
34
Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. ( 17906381 )
2007
35
Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. ( 17549341 )
2007
36
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 17943850 )
2007
37
Two-tier grading system for ovarian epithelial cancer: has its time arrived? ( 17667555 )
2007
38
[Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. ( 17673045 )
2007
39
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. ( 17107625 )
2006
40
Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. ( 16936295 )
2006
41
Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. ( 16961294 )
2006
42
Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons. ( 16707225 )
2006
43
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. ( 15867369 )
2005
44
Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. ( 15944801 )
2005
45
Aromatase expression in ovarian epithelial cancers. ( 15748828 )
2005
46
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. ( 15171311 )
2004
47
Borderline ovarian epithelial cancer. ( 21213507 )
2004
48
Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). ( 15226774 )
2004
49
Oncogenic pathways implicated in ovarian epithelial cancer. ( 12959183 )
2003
50
Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. ( 12626776 )
2003

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
3 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

Pathways related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

(show all 31)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 AKT2 BIRC5 MUC4 PHB PIK3CA PTGS2
2
Show member pathways
12.34 AKT2 BIRC5 PIK3CA
3
Show member pathways
12.34 AKT2 PIK3CA PTGS2
4 12.22 AKT2 BIRC5 PIK3CA PTGS2
5 12.17 AKT2 BIRC5 PTGS2
6
Show member pathways
12.14 AKT2 BIRC5 PIK3CA
7
Show member pathways
12.09 AKT2 BIRC5 PIK3CA
8
Show member pathways
12.02 AKT2 PIK3CA PTGS2
9 11.67 AKT2 PIK3CA PTGS1
10
Show member pathways
11.65 AKT2 PIK3CA PTGS1 PTGS2
11 11.58 AKT2 PIK3CA PTGS2
12 11.46 AKT2 PIK3CA
13
Show member pathways
11.45 BIRC5 PTGS2
14 11.4 PTGS1 PTGS2
15 11.36 AKT2 PIK3CA PTGS2
16 11.34 AKT2 PIK3CA
17 11.32 BIRC5 PTGS2
18 11.25 AKT2 PIK3CA
19 11.24 AKT2 PIK3CA
20 11.2 AKT2 BIRC5
21 11.2 AKT2 BIRC5 PIK3CA
22 11.15 BIRC5 PTGS2
23 11.04 PTGS1 PTGS2
24 10.99 PTGS1 PTGS2
25
Show member pathways
10.97 PTGS1 PTGS2
26 10.89 PTGS1 PTGS2
27 10.86 PTGS1 PTGS2
28 10.76 AKT2 PIK3CA
29 10.74 PTGS1 PTGS2
30 10.66 AKT2 PIK3CA PTGS1 PTGS2
31 10.61 PTGS1 PTGS2

GO Terms for Ovarian Epithelial Cancer

Biological processes related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell death GO:0010942 9.26 PHB PTGS2
2 prostaglandin metabolic process GO:0006693 9.16 PTGS1 PTGS2
3 prostaglandin biosynthetic process GO:0001516 8.96 PTGS1 PTGS2
4 cyclooxygenase pathway GO:0019371 8.62 PTGS1 PTGS2

Molecular functions related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.33 BIRC5 PHB PTGS2
2 peroxidase activity GO:0004601 8.96 PTGS1 PTGS2
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....